AU2016250905B2 - Generation of muscle-lineage cells from stem cells - Google Patents

Generation of muscle-lineage cells from stem cells Download PDF

Info

Publication number
AU2016250905B2
AU2016250905B2 AU2016250905A AU2016250905A AU2016250905B2 AU 2016250905 B2 AU2016250905 B2 AU 2016250905B2 AU 2016250905 A AU2016250905 A AU 2016250905A AU 2016250905 A AU2016250905 A AU 2016250905A AU 2016250905 B2 AU2016250905 B2 AU 2016250905B2
Authority
AU
Australia
Prior art keywords
cells
satellite
days
pluripotent stem
pax3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2016250905A
Other languages
English (en)
Other versions
AU2016250905A1 (en
AU2016250905A8 (en
Inventor
Leslie Caron
Uli Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sonic Master Ltd
Original Assignee
Sonic Master Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sonic Master Ltd filed Critical Sonic Master Ltd
Publication of AU2016250905A1 publication Critical patent/AU2016250905A1/en
Publication of AU2016250905A8 publication Critical patent/AU2016250905A8/en
Assigned to Genea Biocells USA (Holdings), Inc. reassignment Genea Biocells USA (Holdings), Inc. Request for Assignment Assignors: GENEA IP HOLDINGS PTY LTD
Assigned to SONIC MASTER LIMITED reassignment SONIC MASTER LIMITED Request for Assignment Assignors: Genea Biocells USA (Holdings), Inc.
Application granted granted Critical
Publication of AU2016250905B2 publication Critical patent/AU2016250905B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
    • C12N5/0659—Satellite cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
AU2016250905A 2015-04-22 2016-04-22 Generation of muscle-lineage cells from stem cells Ceased AU2016250905B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562151352P 2015-04-22 2015-04-22
US62/151,352 2015-04-22
PCT/AU2016/000144 WO2016168890A1 (en) 2015-04-22 2016-04-22 Generation of muscle-lineage cells from stem cells

Publications (3)

Publication Number Publication Date
AU2016250905A1 AU2016250905A1 (en) 2017-11-09
AU2016250905A8 AU2016250905A8 (en) 2018-03-15
AU2016250905B2 true AU2016250905B2 (en) 2022-02-10

Family

ID=60254709

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016250905A Ceased AU2016250905B2 (en) 2015-04-22 2016-04-22 Generation of muscle-lineage cells from stem cells

Country Status (7)

Country Link
US (1) US20180346879A1 (enExample)
EP (1) EP3286301B1 (enExample)
JP (1) JP7055638B2 (enExample)
CN (1) CN107709545A (enExample)
AU (1) AU2016250905B2 (enExample)
CA (1) CA2983332A1 (enExample)
WO (1) WO2016168890A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3176380A1 (en) 2014-11-21 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and compositions for targeted genetic modification using paired guide rnas
US11318167B2 (en) 2015-12-11 2022-05-03 The Johns Hopkins University Isolation of fusion-competent myoblasts and therapeutic applications thereof related to muscular dystrophy
WO2017188458A1 (ja) * 2016-04-27 2017-11-02 武田薬品工業株式会社 骨格筋前駆細胞及び骨格筋細胞の製造方法
WO2017201476A1 (en) 2016-05-20 2017-11-23 Regeneron Pharmaceuticals, Inc. Methods for breaking immunological tolerance using multiple guide rnas
CA3044691A1 (en) 2016-10-26 2018-05-03 Genea Biocells USA (Holdings), Inc. Improved generation of muscle lineage cells and therapeutic uses thereof
US12365875B2 (en) 2017-01-06 2025-07-22 The Regents Of The University Of California Methods for generating skeletal muscle progenitor cells
CN107937338B (zh) * 2017-11-30 2021-08-03 中山大学 一种来自多能干细胞的中胚层谱系间充质干细胞及其制备方法
CN110859854A (zh) * 2018-08-08 2020-03-06 上海市东方医院 治疗神经源性肌肉萎缩的药物组合物及其制法和应用
JP7033095B2 (ja) * 2019-03-04 2022-03-09 日清食品ホールディングス株式会社 三次元筋組織とその製造方法
JP2023502269A (ja) * 2019-11-20 2023-01-23 ヴィータ セラピューティクス インク． 低免疫原性の筋肉前駆体細胞の遺伝子改変的調製方法
JP7540893B2 (ja) * 2020-02-27 2024-08-27 テルモ株式会社 Ｃｄ５６陽性細胞の比率を高めるための組成物
CN111826451A (zh) * 2020-09-11 2020-10-27 中国肉类食品综合研究中心 实时荧光定量pcr检测猪肌肉调节因子的引物组及其应用
US20240018479A1 (en) * 2020-10-26 2024-01-18 University Of Massachusetts Methods and compositions for treatment of muscle disease with ipsc-induced human skeletal muscle stem cells
WO2022140300A1 (en) * 2020-12-22 2022-06-30 Ixcells Biotechnolgies Usa, Inc. Methods and compositions for differentiating skeletal muscle
CA3225396A1 (en) * 2021-08-09 2023-02-16 Neta LAVON Muscle cells differentiated from pluripotent cells, methods of producing same and use thereof
KR20240152443A (ko) * 2023-04-12 2024-10-22 이엔셀 주식회사 근력 약화 관련 질환 치료제 스크리닝 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013138623A1 (en) * 2012-03-14 2013-09-19 Children's Medical Center Corporation High-throughput image-based chemical screening in zebrafish blastomere cell culture

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143842A (en) 1988-11-01 1992-09-01 The University Of Colorado Foundation, Inc. Media for normal human muscle satellite cells
WO2007126077A1 (ja) * 2006-04-28 2007-11-08 Asubio Pharma Co., Ltd. 多能性幹細胞から心筋細胞を分化誘導する方法
AU2010355614B2 (en) * 2010-06-13 2015-07-02 Institute Of Biophysics, Chinese Academy Of Sciences Methods and compositions for preparing cardiomyocytes from stem cells and uses thereof
EP2891712A4 (en) * 2012-07-23 2016-04-06 Inst Biophysics Cn Acad Sci METHOD FOR INDUCTING PLURIPOTENTAL STEM CELLS FOR DIFFERENTIATING VENTRICULAR IN MYOCYTES IN VITRO
AU2014268197A1 (en) * 2014-02-11 2015-08-27 Monash University Muscle cell production
CN104293730B (zh) * 2014-09-23 2017-07-28 云南中科灵长类生物医学重点实验室 多能干细胞体外定向分化为心肌细胞的方法
JP6845500B2 (ja) * 2014-12-29 2021-03-17 国立大学法人京都大学 骨格筋前駆細胞の製造方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013138623A1 (en) * 2012-03-14 2013-09-19 Children's Medical Center Corporation High-throughput image-based chemical screening in zebrafish blastomere cell culture

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BORCHIN B et al., "Derivation and FACS-Mediated Purification of PAX3+/PAX7+ Skeletal Muscle Precursors from Human Pluripotent Stem Cells", Stem Cell Reports, (2013), vol. 1, pages 620 - 631 *
MAHMOOD A et al., "Enhanced differentiation of human embryonic stem cells to mesenchymal progenitors by inhibition of TGF-ß/Activin/Nodal signaling using SB- 431542", Journal of Bone and Mineral Research, 2010, vol. 25, pages 1216-1233 *
SHELTON M et al., "Derivation and Expansion of PAX7-Positive Muscle Progenitors from Human and Mouse Embryonic Stem Cells", Stem Cell Reports, (2014), vol. 3, pages 516 - 529 *

Also Published As

Publication number Publication date
EP3286301B1 (en) 2021-07-28
US20180346879A1 (en) 2018-12-06
EP3286301A4 (en) 2019-02-20
AU2016250905A1 (en) 2017-11-09
CA2983332A1 (en) 2016-10-27
JP2018518943A (ja) 2018-07-19
WO2016168890A1 (en) 2016-10-27
AU2016250905A8 (en) 2018-03-15
CN107709545A (zh) 2018-02-16
WO2016168890A8 (en) 2017-11-30
JP7055638B2 (ja) 2022-04-18
EP3286301A1 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
AU2016250905B2 (en) Generation of muscle-lineage cells from stem cells
KR101993027B1 (ko) 줄기 세포 마이크로입자
US7642091B2 (en) Human trophoblast stem cells and use thereof
CN104703609B (zh) 干细胞微粒
Zahabi et al. A new efficient protocol for directed differentiation of retinal pigmented epithelial cells from normal and retinal disease induced pluripotent stem cells
ES2927175T3 (es) Método de producción de micropartículas
US20150250824A1 (en) Methods and compositions for expansion of stem cells and other cells
US20240002811A1 (en) Methods for Generation for Pluripotent and Multipotent Cells
CN114292817A (zh) 从多能性干细胞诱导细胞免疫治疗用t细胞的方法
Jurga et al. Neurogenic potential of human umbilical cord blood: Neural‐like stem cells depend on previous long‐term culture conditions
US20100190250A1 (en) Methods of Rejuvenating Cells In Vitro and In Vivo
WO2007106200A2 (en) Expansion and differentiation of neural stem cells under low oxygen conditions
Loperfido et al. Pluripotent stem cells for gene therapy of degenerative muscle diseases
AU2016366158A1 (en) Methods for the re-derivation of diverse pluripotent stem cell-derived brown fat cells
EP3481944A1 (en) Means and methods for the generation of oligodendrocytes
EP2647384B1 (en) IMMUNOTHERAPY USING ALLO-NKT CELLS, CELLS FOR IMMUNOTHERAPY IN WHICH alpha CHAIN OF T-CELL RECEPTOR (TCR) GENE HAS BEEN REARRANGED TO UNIFORM V alpha-J alpha , AND BANKING OF NKT CELLS DERIVED FROM SAID CELLS
Varela et al. Generation of Human β-Thalassemia Induced Pluripotent Cell Lines by Reprogramming of Bone Marrow–Derived Mesenchymal Stromal Cells Using Modified mRNA
US20230285353A1 (en) A chemical cocktail driving expansion of myogenic stem cells
US20250197803A1 (en) A method of differentiating an induced pluripotent stem cell into a retinal pigment epithelial cell, a retinal pigment epithelial cell and methods of using the retinal pigment epithelial cell
WO2023010209A1 (en) Neural progenitor cells and therapeutic uses of same
Belfiore et al. Combinatorial expression of glial transcription factors induces Schwann cell‐specific gene expression in mouse embryonic fibroblasts
US10590387B2 (en) CD133+ cells and method for expanding
Bonsi et al. Stem cells
Buzanska Human Neural Stem Cells: From Generation to Differentiation and Application
TWI769410B (zh) 新穎誘導性多能幹細胞(ipscs)及其應用

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 31 , NO 44 , PAGE(S) 6426 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME GENEA IP HOLDINGS PTY LTD, APPLICATION NO. 2016250905, UNDER INID (31) CORRECT THE PRIORITY TO 62/151,352

PC1 Assignment before grant (sect. 113)

Owner name: GENEA BIOCELLS USA (HOLDINGS), INC.

Free format text: FORMER APPLICANT(S): GENEA IP HOLDINGS PTY LTD

PC1 Assignment before grant (sect. 113)

Owner name: SONIC MASTER LIMITED

Free format text: FORMER APPLICANT(S): GENEA BIOCELLS USA (HOLDINGS), INC.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired